{"success":true,"data":{"pressRelease":{"id":"59585","rtpr_id":"nWkr9h6y5T","ticker":"HLUNA","exchange":"Nasdaq Copenhagen","all_tickers":["HLUNA"],"title":"Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026","author":"Cision","published_at":"2026-06-10T06:00:05.790Z","article_body":"H. Lundbeck A/S* Upcoming presentations at ENDO 2026 highlight Lundbeck’s\nFocused Innovator strategy and continued expansion into rare neuroendocrine\ndiseases with high unmet medical needs\n* The scientific program showcases Lundbeck’s investigational neurohormonal\nand neuroimmunological targeted therapeutic candidates, asedebart and Lu\nAG22515, respectively  \n* Preliminary Phase II data for asedebart, an investigational\nanti-adrenocorticotropic hormone (ACTH) monoclonal antibody in Cushing’s\ndisease (CD), demonstrate Lundbeck’s biomarker-supported approach to\nevaluating novel therapeutic mechanisms in rare endocrine disorders\n* Preclinical characterization of the CD40L blocker Lu AG22515 will be shared\nas well as data from a patient study in thyroid eye disease (TED,) reflecting\nexploratory studies of CD40L modulation in autoimmune disease biology, with\npotential relevance to neuroinflammation implicated in several neurological\nand endocrine diseases\nValby, Denmark, Wednesday 10 June 2026 – H. Lundbeck A/S (Lundbeck) today\nannounced that new data will be presented at the 2026 Endocrine Society’s\nAnnual Meeting (ENDO), taking place June 13–16 in Chicago, Illinois, U.S.\nLundbeck will present preliminary Phase II data for asedebart (Lu AG13909) in\nCD, reflecting Lundbeck’s expansion into neuroendocrine diseases.  In\naddition, preclinical and Phase Ib clinical exploratory findings on Lu AG22515\nin patients with TED will be shared, providing insights into the broader\ntherapeutic potential of CD40L pathway modulation across inflammatory and\nimmunological disorders.\n\n“Lundbeck’s presence at ENDO 2026 reflects how we have expanded upon our\nneuroscience heritage in recent years. This involves pursuing biological drug\ntargets within hormonal and immunological signaling pathways that offer the\npotential to deliver highly differentiated therapeutics for neurological and\nneuroendocrinology indications with high medical unmet need,” said Johan\nLuthman, EVP and Head of Research & Development at Lundbeck. “Through this\napproach, we have made significant progress across our rare disease programs,\nenabling decisive, biomarker-supported patient studies that facilitate early\ndevelopment decisions, as exemplified by our ENDO 2026 scientific program.”\n\nAsedebart data provide insight into ACTH neutralization in Cushing’s disease\n\nAmong the highlights are preliminary Phase II data for asedebart, an\ninvestigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody,\nbeing evaluated in adults with CD.\n\nCD is a rare neuroendocrine disorder typically caused by an ACTH-secreting\npituitary adenoma, leading to chronic excess cortisol production and\nsubstantial physical and neuropsychiatric burden.(1,2) While surgery is the\nstandard first-line treatment, many patients experience persistent or\nrecurrent disease despite available pharmacologic options, and significant\nunmet need remains.\n\nThe Phase II data being presented include impact on urinary free cortisol\n(UFC) levels following individualized dose titration of asedebart, alongside\nsafety and tolerability assessments, supporting further understanding of\ndirect ACTH neutralization in CD.\n\nThe CD study builds on earlier Phase I findings in classic congenital adrenal\nhyperplasia (CAH) (ClinicalTrials.gov: NCT05669950\n(https://clinicaltrials.gov/study/NCT05669950)), which showed pharmacodynamic\neffects on key adrenal steroid biomarkers. The CD data presented at ENDO add\nto Lundbeck’s evaluation of targeting ACTH-driven endocrine conditions with\nlinks to brain function — using early clinical and pharmacodynamic evidence\nto assess therapeutic potential in areas of significant unmet need.\n\nAsedebart has received Orphan Drug Designation (ODD) for CAH in the European\nUnion and the United States as well as ODD in Japan for the treatment of\npatients with CD and CAH.\n\nLu AG22515 data provide insight into CD40L pathway biology\n\nAt ENDO, Lundbeck will also present preclinical characterization findings for\nthe investigational CD40L blocker Lu AG22515. CD40L is a key immune signaling\nmolecule heavily implicated in a wide range of immune disorders, neurology and\npotentially endocrine conditions.(3) The presentation will describe the\ninhibitory effect and PK/PD profile of Lu AG22515, including effects on\nmembrane-bound and soluble CD40L, B-cell activation and differentiation,\nproinflammatory cytokine production and in vivo antibody responses.\n\nAdditionally, clinical findings will be presented from an exploratory Phase Ib\nopen label study on AG22515 in TED patients. TED is an autoimmune disorder\nthat can cause proptosis, diplopia, pain, disfigurement and, in severe cases,\nvisual impairment or vision loss.(4  )The presentation will cover three\nareas: pharmacodynamic assessments designed to evaluate CD40L pathway\nengagement, safety and tolerability, and preliminary clinical efficacy in TED,\nincluding effects on proptosis and other measures of disease activity. The\ndata further enhance the understanding of CD40L pathway modulation in TED and\nother CD40L-mediated immune disorders.\n\nAsedebart and Lu AG22515 are investigational drugs not approved for marketing\nby any regulatory authority worldwide, and the efficacy and safety of both\nmolecules have not been established.\n\nDetails of Lundbeck presentations at ENDO 2026\n\n Therapeutic Area           Presentation content                                                                                                                                                                               Presentation Type                   Reference          \n Cushing’s disease          A Phase II, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Novel Anti-ACTH Antibody Asedebart in Adults with Cushing’s Disease    Oral presentation                   Sun 14 June        \n  Asedebart                                                                                                                                                                                                                                                         14:45-15:00 CT    \n  Lu AG13909                                                                                                                                                                                                                                                        Room W183BC       \n Thyroid eye disease (TED)  Results From a Phase 1b Trial Evaluating CD40-Ligand Blocker Lu AG22515 in Patients with Moderate-to-Severe Thyroid Eye Disease                                                                    Oral presentation                   Mon 15 June        \n  Lu AG22515                                                                                                                                                                                                                                                        14:15-14:30 CT    \n                                                                                                                                                                                                                                                                    W184ABC           \n Thyroid eye disease (TED)  Preclinical Pharmacokinetic and Pharmacodynamic Profile of Lu AG22515, a CD40-Ligand Blocker in Development for Thyroid Eye Disease                                                                Rapid-fire presentation and poster  Sun 14 June        \n  Lu AG22515                                                                                                                                                                                                                                                        09:00- 16:00 CT   \n                                                                                                                                                                                                                                                                    ENDOExpo;         \n                                                                                                                                                                                                                                                                    Poster floor      \n\nAbout Cushing’s disease\n\nCushing’s disease is a rare neuro-endocrine disorder caused by a pituitary\nadenoma that secretes excess ACTH, leading to chronic overproduction of\ncortisol.(1)  The condition is associated with significant morbidity and\nincreased mortality, and patients may experience a wide range of physical and\nneuropsychiatric symptoms.(2) First-line treatment is surgical removal of the\ntumor; however, not all patients are eligible, achieve sustained remission, or\nbenefit fully from current available treatment options, highlighting an\nongoing unmet need for effective and well-tolerated therapies.\n\nAbout asedebart (Lu AG13909)\n\nAsedebart is a humanized anti-ACTH monoclonal antibody designed specifically\nto recognize ACTH with high affinity. It blocks the binding of ACTH to the\nmelanocortin 2 receptor in the adrenal glands and thereby inhibits the\nneurohormonal signalling of ACTH. This inhibition causes a decreased secretion\nof glucocorticoids, mineralocorticoids and androgens from the adrenal glands.\n(5,6) ACTH plays a key role in the biosynthesis of adrenal steroids(7) and is\ntherefore considered a promising therapeutic target in conditions\ncharacterized by elevated ACTH levels.(6) \n \n\nAbout thyroid eye disease (TED)\n\nThyroid eye disease (TED) is a rare autoimmune condition associated with\nthyroid dysfunction, characterized by inflammation and expansion of\nretro-orbital tissues. Clinical manifestations include proptosis,\ndouble-vision, pain, swelling, and disfigurement, and in severe cases may lead\nto visual impairment or loss of vision. TED can have a substantial impact on\ndaily functioning, quality of life and psychological wellbeing.(4)\n\nCurrent treatments are not optimal for all patients and may be associated with\nsignificant adverse effects, highlighting the need for additional therapeutic\napproaches that target underlying autoimmune disease biology. (4)\n \n\nAbout Lu AG22515\n\nLu AG22515 is an investigational CD40L blocker being evaluated in CD40L\nmediated autoimmune diseases. Lu AG22515 is a recombinant fusion protein that\nbinds CD40 ligand (CD40L) and human serum albumin (HSA) to extend half-life.\nBy blocking the interaction between CD40L and the CD40 receptor, Lu AG22515 is\ndesigned to modulate a key immune co-stimulatory pathway involved in B-cell\nactivation, antibody responses and inflammatory signaling.\n\nContacts\n\n Anders Crillesen                                Jens Høyer                                  \n Senior Director, External & Internal Relations  Vice President, Head of Investor Relations  \n AECE@lundbeck.com                               JSHR@lundbeck.com                           \n +45 27 79 12 86                                 +45 30 83 45 01                             \n                                                                                             \n                                                                                             \n \nAbout H. Lundbeck A/S\n\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world’s population, and the\neffects are felt throughout society. With the rapidly improving understanding\nof the biology of the brain, we hold ourselves accountable for advancing brain\nhealth by curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families, and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect with\nus via LinkedIn (https://www.linkedin.com/company/lundbeck/).\n\n \n\nReferences:\n\n1. Lacroix A, Feelders RA, Stratakis CA, et al. Lancet.\n2015;386(9996):913–927\n\n2. Sharma ST, Nieman LK, Feelders RA. Pituitary. 2015;18(2):188–194\n\n3. Ots HD, Tracz JA, Vinokuroff KE, et al. Int J Mol Sci. 2022;23(8):4115\n\n4. Dhaliwal NK, Razzaq L. Cureus. 2025;17(6):e86483.\n\n5. Lundbeck. Data on file\n\n6. Feldhaus AL, et al. Endocrinology 2017;158(1):1-8\n\n7. Xing Y, et al. J Endocrinol 2011;209(3):327-35\n\n\n \n\nH. Lundbeck A/S\n\nOttiliavej 9, 2500 Valby, Denmark\n\n+45 3630 1311\n\ninfo@lundbeck.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/lundbeck-to-present-new-patient-data-on-neuroendocrine-and-neuroimmunology-programs-at-endo-2026%2Cc4359848\n\nENDO curtain raiser_Final\n(https://mb.cision.com/Main/18215/4359848/4142804.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr9h6y5T","title":"Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026","author":"Cision","ticker":"HLUNA","created":"2026-06-10T06:00:05.790Z","tickers":["HLUNA"],"exchange":"Nasdaq Copenhagen","article_body":"H. Lundbeck A/S* Upcoming presentations at ENDO 2026 highlight Lundbeck’s\nFocused Innovator strategy and continued expansion into rare neuroendocrine\ndiseases with high unmet medical needs\n* The scientific program showcases Lundbeck’s investigational neurohormonal\nand neuroimmunological targeted therapeutic candidates, asedebart and Lu\nAG22515, respectively  \n* Preliminary Phase II data for asedebart, an investigational\nanti-adrenocorticotropic hormone (ACTH) monoclonal antibody in Cushing’s\ndisease (CD), demonstrate Lundbeck’s biomarker-supported approach to\nevaluating novel therapeutic mechanisms in rare endocrine disorders\n* Preclinical characterization of the CD40L blocker Lu AG22515 will be shared\nas well as data from a patient study in thyroid eye disease (TED,) reflecting\nexploratory studies of CD40L modulation in autoimmune disease biology, with\npotential relevance to neuroinflammation implicated in several neurological\nand endocrine diseases\nValby, Denmark, Wednesday 10 June 2026 – H. Lundbeck A/S (Lundbeck) today\nannounced that new data will be presented at the 2026 Endocrine Society’s\nAnnual Meeting (ENDO), taking place June 13–16 in Chicago, Illinois, U.S.\nLundbeck will present preliminary Phase II data for asedebart (Lu AG13909) in\nCD, reflecting Lundbeck’s expansion into neuroendocrine diseases.  In\naddition, preclinical and Phase Ib clinical exploratory findings on Lu AG22515\nin patients with TED will be shared, providing insights into the broader\ntherapeutic potential of CD40L pathway modulation across inflammatory and\nimmunological disorders.\n\n“Lundbeck’s presence at ENDO 2026 reflects how we have expanded upon our\nneuroscience heritage in recent years. This involves pursuing biological drug\ntargets within hormonal and immunological signaling pathways that offer the\npotential to deliver highly differentiated therapeutics for neurological and\nneuroendocrinology indications with high medical unmet need,” said Johan\nLuthman, EVP and Head of Research & Development at Lundbeck. “Through this\napproach, we have made significant progress across our rare disease programs,\nenabling decisive, biomarker-supported patient studies that facilitate early\ndevelopment decisions, as exemplified by our ENDO 2026 scientific program.”\n\nAsedebart data provide insight into ACTH neutralization in Cushing’s disease\n\nAmong the highlights are preliminary Phase II data for asedebart, an\ninvestigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody,\nbeing evaluated in adults with CD.\n\nCD is a rare neuroendocrine disorder typically caused by an ACTH-secreting\npituitary adenoma, leading to chronic excess cortisol production and\nsubstantial physical and neuropsychiatric burden.(1,2) While surgery is the\nstandard first-line treatment, many patients experience persistent or\nrecurrent disease despite available pharmacologic options, and significant\nunmet need remains.\n\nThe Phase II data being presented include impact on urinary free cortisol\n(UFC) levels following individualized dose titration of asedebart, alongside\nsafety and tolerability assessments, supporting further understanding of\ndirect ACTH neutralization in CD.\n\nThe CD study builds on earlier Phase I findings in classic congenital adrenal\nhyperplasia (CAH) (ClinicalTrials.gov: NCT05669950\n(https://clinicaltrials.gov/study/NCT05669950)), which showed pharmacodynamic\neffects on key adrenal steroid biomarkers. The CD data presented at ENDO add\nto Lundbeck’s evaluation of targeting ACTH-driven endocrine conditions with\nlinks to brain function — using early clinical and pharmacodynamic evidence\nto assess therapeutic potential in areas of significant unmet need.\n\nAsedebart has received Orphan Drug Designation (ODD) for CAH in the European\nUnion and the United States as well as ODD in Japan for the treatment of\npatients with CD and CAH.\n\nLu AG22515 data provide insight into CD40L pathway biology\n\nAt ENDO, Lundbeck will also present preclinical characterization findings for\nthe investigational CD40L blocker Lu AG22515. CD40L is a key immune signaling\nmolecule heavily implicated in a wide range of immune disorders, neurology and\npotentially endocrine conditions.(3) The presentation will describe the\ninhibitory effect and PK/PD profile of Lu AG22515, including effects on\nmembrane-bound and soluble CD40L, B-cell activation and differentiation,\nproinflammatory cytokine production and in vivo antibody responses.\n\nAdditionally, clinical findings will be presented from an exploratory Phase Ib\nopen label study on AG22515 in TED patients. TED is an autoimmune disorder\nthat can cause proptosis, diplopia, pain, disfigurement and, in severe cases,\nvisual impairment or vision loss.(4  )The presentation will cover three\nareas: pharmacodynamic assessments designed to evaluate CD40L pathway\nengagement, safety and tolerability, and preliminary clinical efficacy in TED,\nincluding effects on proptosis and other measures of disease activity. The\ndata further enhance the understanding of CD40L pathway modulation in TED and\nother CD40L-mediated immune disorders.\n\nAsedebart and Lu AG22515 are investigational drugs not approved for marketing\nby any regulatory authority worldwide, and the efficacy and safety of both\nmolecules have not been established.\n\nDetails of Lundbeck presentations at ENDO 2026\n\n Therapeutic Area           Presentation content                                                                                                                                                                               Presentation Type                   Reference          \n Cushing’s disease          A Phase II, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Novel Anti-ACTH Antibody Asedebart in Adults with Cushing’s Disease    Oral presentation                   Sun 14 June        \n  Asedebart                                                                                                                                                                                                                                                         14:45-15:00 CT    \n  Lu AG13909                                                                                                                                                                                                                                                        Room W183BC       \n Thyroid eye disease (TED)  Results From a Phase 1b Trial Evaluating CD40-Ligand Blocker Lu AG22515 in Patients with Moderate-to-Severe Thyroid Eye Disease                                                                    Oral presentation                   Mon 15 June        \n  Lu AG22515                                                                                                                                                                                                                                                        14:15-14:30 CT    \n                                                                                                                                                                                                                                                                    W184ABC           \n Thyroid eye disease (TED)  Preclinical Pharmacokinetic and Pharmacodynamic Profile of Lu AG22515, a CD40-Ligand Blocker in Development for Thyroid Eye Disease                                                                Rapid-fire presentation and poster  Sun 14 June        \n  Lu AG22515                                                                                                                                                                                                                                                        09:00- 16:00 CT   \n                                                                                                                                                                                                                                                                    ENDOExpo;         \n                                                                                                                                                                                                                                                                    Poster floor      \n\nAbout Cushing’s disease\n\nCushing’s disease is a rare neuro-endocrine disorder caused by a pituitary\nadenoma that secretes excess ACTH, leading to chronic overproduction of\ncortisol.(1)  The condition is associated with significant morbidity and\nincreased mortality, and patients may experience a wide range of physical and\nneuropsychiatric symptoms.(2) First-line treatment is surgical removal of the\ntumor; however, not all patients are eligible, achieve sustained remission, or\nbenefit fully from current available treatment options, highlighting an\nongoing unmet need for effective and well-tolerated therapies.\n\nAbout asedebart (Lu AG13909)\n\nAsedebart is a humanized anti-ACTH monoclonal antibody designed specifically\nto recognize ACTH with high affinity. It blocks the binding of ACTH to the\nmelanocortin 2 receptor in the adrenal glands and thereby inhibits the\nneurohormonal signalling of ACTH. This inhibition causes a decreased secretion\nof glucocorticoids, mineralocorticoids and androgens from the adrenal glands.\n(5,6) ACTH plays a key role in the biosynthesis of adrenal steroids(7) and is\ntherefore considered a promising therapeutic target in conditions\ncharacterized by elevated ACTH levels.(6) \n \n\nAbout thyroid eye disease (TED)\n\nThyroid eye disease (TED) is a rare autoimmune condition associated with\nthyroid dysfunction, characterized by inflammation and expansion of\nretro-orbital tissues. Clinical manifestations include proptosis,\ndouble-vision, pain, swelling, and disfigurement, and in severe cases may lead\nto visual impairment or loss of vision. TED can have a substantial impact on\ndaily functioning, quality of life and psychological wellbeing.(4)\n\nCurrent treatments are not optimal for all patients and may be associated with\nsignificant adverse effects, highlighting the need for additional therapeutic\napproaches that target underlying autoimmune disease biology. (4)\n \n\nAbout Lu AG22515\n\nLu AG22515 is an investigational CD40L blocker being evaluated in CD40L\nmediated autoimmune diseases. Lu AG22515 is a recombinant fusion protein that\nbinds CD40 ligand (CD40L) and human serum albumin (HSA) to extend half-life.\nBy blocking the interaction between CD40L and the CD40 receptor, Lu AG22515 is\ndesigned to modulate a key immune co-stimulatory pathway involved in B-cell\nactivation, antibody responses and inflammatory signaling.\n\nContacts\n\n Anders Crillesen                                Jens Høyer                                  \n Senior Director, External & Internal Relations  Vice President, Head of Investor Relations  \n AECE@lundbeck.com                               JSHR@lundbeck.com                           \n +45 27 79 12 86                                 +45 30 83 45 01                             \n                                                                                             \n                                                                                             \n \nAbout H. Lundbeck A/S\n\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world’s population, and the\neffects are felt throughout society. With the rapidly improving understanding\nof the biology of the brain, we hold ourselves accountable for advancing brain\nhealth by curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families, and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect with\nus via LinkedIn (https://www.linkedin.com/company/lundbeck/).\n\n \n\nReferences:\n\n1. Lacroix A, Feelders RA, Stratakis CA, et al. Lancet.\n2015;386(9996):913–927\n\n2. Sharma ST, Nieman LK, Feelders RA. Pituitary. 2015;18(2):188–194\n\n3. Ots HD, Tracz JA, Vinokuroff KE, et al. Int J Mol Sci. 2022;23(8):4115\n\n4. Dhaliwal NK, Razzaq L. Cureus. 2025;17(6):e86483.\n\n5. Lundbeck. Data on file\n\n6. Feldhaus AL, et al. Endocrinology 2017;158(1):1-8\n\n7. Xing Y, et al. J Endocrinol 2011;209(3):327-35\n\n\n \n\nH. Lundbeck A/S\n\nOttiliavej 9, 2500 Valby, Denmark\n\n+45 3630 1311\n\ninfo@lundbeck.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/lundbeck-to-present-new-patient-data-on-neuroendocrine-and-neuroimmunology-programs-at-endo-2026%2Cc4359848\n\nENDO curtain raiser_Final\n(https://mb.cision.com/Main/18215/4359848/4142804.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-06-10T06:00:06.239147678Z","server_sent_at_ms":1781071206239},"received_at":"2026-06-10T06:00:06.388Z","source_url":"https://news.cision.com/h--lundbeck-a-s/r/lundbeck-to-present-new-patient-data-on-neuroendocrine-and-neuroimmunology-programs-at-endo-2026%2Cc4359848"},"analysis":{"id":"49011","press_release_id":"59585","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Lundbeck will present preliminary Phase II data for asedebart, an anti-ACTH monoclonal antibody, in patients with Cushing’s disease at ENDO 2026.\n\nThe company will also share preclinical and Phase Ib clinical findings for Lu AG22515, a CD40L blocker, in patients with thyroid eye disease.\n\nThese presentations highlight Lundbeck’s expansion into rare neuroendocrine and neuroimmunology indications, leveraging biomarker-supported approaches to evaluate novel therapeutic mechanisms.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Lundbeck advances rare-disease pipeline with Phase II asedebart data in Cushing’s and Phase Ib Lu AG22515 data in TED."},"keyFigures":{"drugName":"asedebart (Lu AG13909)","phaseOfTrial":"Phase II","customDimensions":{"conference":"ENDO 2026","conference_dates":"June 13–16, 2026","second_drug_name":"Lu AG22515","second_drug_phase":"Phase Ib"}},"quotedText":"Lundbeck’s presence at ENDO 2026 reflects how we have expanded upon our neuroscience heritage in recent years. This involves pursuing biological drug targets within hormonal and immunological signaling pathways that offer the potential to deliver highly differentiated therapeutics for neurological and neuroendocrinology indications with high medical unmet need","namedEntities":{"people":[{"name":"Johan Luthman","role":"EVP and Head of Research & Development"},{"name":"Anders Crillesen","role":"Senior Director, External & Internal Relations"},{"name":"Jens Høyer","role":"Vice President, Head of Investor Relations"}],"products":["asedebart","Lu AG13909","Lu AG22515"],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA","relationship":"filer"},{"name":"Endocrine Society","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Presentation of preliminary Phase II data for lead asset asedebart in Cushing’s disease and Phase Ib data for Lu AG22515 in TED. Positive de-risking signal for two rare-disease programs, but early-stage data without binary regulatory outcomes."},"tickerRelevance":{"others":[],"primary":"HLUNA"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"clinical_data_presentation","sectorWeight":"biotech/pharma","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Lundbeck will present preliminary Phase II data for asedebart, an anti-ACTH monoclonal antibody, in patients with Cushing’s disease at ENDO 2026.\n\nThe company will also share preclinical and Phase Ib clinical findings for Lu AG22515, a CD40L blocker, in patients with thyroid eye disease.\n\nThese presentations highlight Lundbeck’s expansion into rare neuroendocrine and neuroimmunology indications, leveraging biomarker-supported approaches to evaluate novel therapeutic mechanisms.","key_figures":{"drugName":"asedebart (Lu AG13909)","phaseOfTrial":"Phase II","customDimensions":{"conference":"ENDO 2026","conference_dates":"June 13–16, 2026","second_drug_name":"Lu AG22515","second_drug_phase":"Phase Ib"}},"named_entities":{"people":[{"name":"Johan Luthman","role":"EVP and Head of Research & Development"},{"name":"Anders Crillesen","role":"Senior Director, External & Internal Relations"},{"name":"Jens Høyer","role":"Vice President, Head of Investor Relations"}],"products":["asedebart","Lu AG13909","Lu AG22515"],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA","relationship":"filer"},{"name":"Endocrine Society","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-10T06:02:41.065Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"clinical_data_presentation","sectorWeight":"biotech/pharma","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"durationMs":28753,"modelName":"george-droid-qwen-72b"}}